|
1
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Royal RE, Levy C, Turner K, Mathur A,
Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I and
Rosenberg SA: Phase 2 trial of single agent Ipilimumab
(anti-CTLA-4) for locally advanced or metastatic pancreatic
adenocarcinoma. J Immunother. 33:828–833. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hemmi H, Kaisho T, Takeuchi O, Sato S,
Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K and Akira S:
Small anti-viral compounds activate immune cells via the TLR7
MyD88-dependent signaling pathway. Nat Immunol. 3:196–200. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peet NP, Baugh LE, Sunder S and Lewis JE:
Synthesis and antiallergic activity of some quinolinones and
imidazoquinolinones. J Med Chem. 28:298–302. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lebwohl M, Dinehart S, Whiting D, Lee PK,
Tawfik N, Jorizzo J, Lee JH and Fox TL: Imiquimod 5% cream for the
treatment of actinic keratosis: Results from two phase III,
randomized, double-blind, parallel group, vehicle-controlled
trials. J Am Acad Dermatol. 50:714–721. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Geisse JK, Rich P, Pandya A, Gross K,
Andres K, Ginkel A and Owens M: Imiquimod 5% cream for the
treatment of superficial basal cell carcinoma: A double-blind,
randomized, vehicle-controlled study. J Am Acad Dermatol.
47:390–398. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Naylor MF, Crowson N, Kuwahara R, Teague
K, Garcia C, Mackinnis C, Haque R, Odom C, Jankey C and Cornelison
RL: Treatment of lentigo maligna with topical imiquimod. Br J
Dermatol. 149 Suppl 66:S66–S70. 2003. View Article : Google Scholar
|
|
9
|
Lyons JF, Wilhelm S, Hibner B and Bollag
G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer.
8:219–225. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Karashima T, Komatsu T, Niimura M, Kawada
C, Kamada M, Inoue K, Udaka K, Kuroda N and Shuin T: Novel
combination therapy with imiquimod and sorafenib for renal cell
carcinoma. Int J Urol. 21:702–706. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vines T and Faunce T: Freedom of
information applications as an ‘evergreening’ tactic: Secretary,
department of health and ageing v iNOVA pharmaceuticals (Australia)
Pty Ltd (2010) 191 FCR 573; [2010]FCA 1442. J Law Med. 19:43–52.
2011.PubMed/NCBI
|
|
12
|
Karashima T, Inoue K, Fukata S, Iiyama T,
Kurabayashi A, Kawada C and Shuin T: Blockade of the vascular
endothelial growth factor-receptor 2 pathway inhibits the growth of
human renal cell carcinoma, RBM1-IT4, in the kidney but not in the
bone of nude mice. Int J Oncol. 30:937–945. 2007.PubMed/NCBI
|
|
13
|
Visseren MJ, van Elsas A, van er Voort EI,
Ressing ME, Kast WM, Schrier PI and Melief CJ: CTL specific for the
tyrosinase autoantigen can be induced from healthy donor blood to
lyse melanoma cells. J Immunol. 154:3991–3998. 1995.PubMed/NCBI
|
|
14
|
Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y,
Nakajima H, Masuda T, Fukuda Y, Kawakatsu M, Morimoto S, et al:
Identification of a WT1 protein-derived peptide, WT1, as a HLA-A
0206-restricted, WT1-specific CTL epitope. Microbiol Immunol.
52:551–558. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Majewski S, Marczak M, Mlynarczyk B,
Benninghoff B and Jablonska S: Imiquimod is a strong inhibitor of
tumor cell-induced angiogenesis. Int J Dermatol. 44:14–19. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vidal D, Matías-Guiu X and Alomar A:
Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and
basal cell carcinoma apoptosis. Br J Dermatol. 151:656–662. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim CH, Ahn JH, Kang SU, Hwang HS, Lee MH,
Pyun JH and Kang HY: Imiquimod induces apoptosis of human
melanocytes. Arch Dermatol Res. 302:301–306. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Escudier B, Eisen T, Stadler WM, Szczylik
C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA,
et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N
Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Santoni M, Berardi R, Amantini C,
Burattini L, Santini D, Santoni G and Cascinu S: Role of natural
and adaptive immunity in renal cell carcinoma response to
VEGFR-TKIs and mTOR inhibitor. Int J Cancer. 134:2772–2777. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cabrera R, Ararat M, Xu Y, Brusko T,
Wasserfall C, Atkinson MA, Chang LJ, Liu C and Nelson DR: Immune
modulation of effector CD4+ and regulatory T cell function by
sorafenib in patients with hepatocellular carcinoma. Cancer Immunol
Immunother. 62:737–746. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Delgado-Charro MB and Guy RH: Transdermal
Drug DeliveryHillary AM, Lloyd AW and Swarbrick J: Drug Delivery
and Targeting: For Pharmacists and Pharmaceutical Scientists.
Taylor & Francis; London and New York: pp. 189–214. 2001
|
|
22
|
Mathias NR and Hussain MA: Non-invasive
systemic drug delivery: Developability considerations for alternate
routes of administration. J Pharm Sci. 99:1–20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oertel W, Ross JS, Eggert K and Adler G:
Rationale for transdermal drug administration in Alzheimer disease.
Neurology. 69 4 Suppl 1:S4–S9. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seeberger LC and Hauser RA: Optimizing
bioavailability in the treatment of Parkinson's disease.
Neuropharmacol. 53:791–800. 2007. View Article : Google Scholar
|
|
25
|
Santini B, Zanoni I, Marzi R, Cigni C,
Bedoni M, Gramatica F, Palugan L, Corsi F, Granucci F and Colombo
M: Cream formulation impact on topical administration of engineered
colloidal nanoparticles. PLoS One. 10:e01263662015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soria I, Myhre P, Horton V, Ellefson P,
McCarville S, Schmitt K and Owens M: Effect of food on the
pharmacokinetics and bioavailability of oral imiquimod relative to
a subcutaneous dose. Int J Clin Pharmacol Ther. 38:476–481. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stein P, Gogoll K, Tenzer S, Schild H,
Stevanovic S, Langguth P and Radsak MP: Efficacy of imiquimod-based
transcutaneous immunization using a nano-dispersed emulsion gel
formulation. PLoS One. 9:e1026642014. View Article : Google Scholar : PubMed/NCBI
|
